Lonial, Sagar http://orcid.org/0000-0002-8322-9323
Nooka, Ajay K. http://orcid.org/0000-0003-4165-6869
Thulasi, Praneetha
Badros, Ashraf Z.
Jeng, Bennie H.
Callander, Natalie S. http://orcid.org/0000-0002-6975-1086
Potter, Heather A.
Sborov, Douglas
Zaugg, Brian E.
Popat, Rakesh
Degli Esposti, Simona
Byrne, Julie
Opalinska, Joanna
Baron, January
Piontek, Trisha
Gupta, Ira
Dana, Reza
Farooq, Asim V.
Colby, Kathryn
Jakubowiak, Andrzej http://orcid.org/0000-0002-2597-6822
Article History
Received: 23 December 2020
Revised: 31 March 2021
Accepted: 26 April 2021
First Online: 26 May 2021
Conflict of interest
: S.L has received grant funding and personal fees from Celgene and Takeda, and personal fees from Novartis, Bristol-Myers Squibb, GSK, Amgen, Merck, and Janssen; A.K.N. has received grant funding and personal fees from GSK, Janssen, Bristol-Myers Squibb, Celgene, Takeda, and Amgen; and personal fees from Oncopeptides and Spectrum; B.H.J. has received compensation from GSK as a consultant; H.A.P. has received funding from the National Eye Institute and the Research to Prevent Blindness organization; D.S. has received personal fees from Celgene, Janssen, and Amgen; B.E.Z. consulted for and received honoraria from GSK; R.P. has received grant funding, personal fees, and non-financial support from Takeda; personal fees and non-financial support from Janssen, Celgene, and GSK, and personal fees from AbbVie; and support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre; S.D.E. has received personal fees from GSK; J.By. is an employee of and hold stocks and shares in GSK and hold stocks and share in Adaptimmune and Novartis; J.O., J.Ba., and T.P. are employees of and hold stocks and shares in GSK; I.G. is an employee of and holds stocks and shares in GSK and holds stocks and shares in Novartis; R.D. is a consultant for GSK, Dompé, Novartis, Alcon, and Kala; has ownership in Aramis Biosciences, Claris Biotherapeutics, and GelMEDIX; and has received funding from the NIH, DOD, and Allergan; A.V.F. is a consultant for GSK; K.C. is a consultant for GSK; A.J. consulted for and received honoraria from AbbVie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Juno, and Karyopharm; P.T., A.Z.B., and N.S.C. declare no competing interests.